Why the study?
Does calcium antagonist monotherapy reduce blood pressure in older patients, those with low renin, or of black race?
Does calcium antagonist monotherapy reduce blood pressure in older patients, those with low renin, or of black race?
Answers are grounded in this paper and cite their sources.
Age, renin levels, and race are important predictors of blood pressure response to calcium antagonists, aiding in personalized antihypertensive treatment strategies.
Ageing is associated with pathophysiological adaptive changes in cardiovascular regulation including reduced baroreflex sensitivity and p-adrenoceptor-mediated cardiac and renal responses. Accordingly, owing to such blunted counterregulation, older patients gain a greater fall in blood pressure for a given peripheral vasodilation, e.g., with a calcium antagonist. Such age-related efficacy may be helped by the calcium antagonist's renal and antialdosterone effects resulting in natriuresis. In open and double-blind treatment trials, calcium antagonists in monotherapy were more effective in reducing blood pressure to normal in older patients with hyper-tension and, for the same reasons. those with a low plasma renin activity or of black race; pretreatment blood pressure was another independent predictor. Age as well as renin and black race help to design antihypertensive treatment strategies with better blood pressure control and better well-being of the patient.
No takes yet. Share an insight, caveat, or question.
Fritz R. Bühler (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: